Gene-editing specialist Bluebird Bio (NASDAQ: BLUE) has been making plenty of noise since 2019, which is when it first earned marketing authorization for one of its breakthrough therapies, beta-thalassemia (TDT) treatment Zynteglo, in Europe. A lot has happened since then: It won more regulatory green lights in Europe and the U.S., but it had to exit the European market.

However, Bluebird stock hasn't been a particularly good investment in this period. Let's see how much people who bought $1,000 worth of the company's shares in early 2019 would have today and what it means for investors going forward.

BLUE Total Return Level data by YCharts.

Continue reading

Source Fool.com